Delfenac may be relevant in situations involving certain distressing symptoms. It is commonly applied across domains where additional symptomatic support is needed for managing various inflammatory and painful conditions.

Therapeutic Contexts of Use

Delfenac may be part of symptomatic management for conditions characterized by periods of heightened symptoms such as Osteoarthritis, Rheumatoid arthritis, and Ankylosing spondylitis. It is relevant for managing symptom clusters that interfere with daily comfort, including persistent joint pain, stiffness, and swelling. It is also used for acute episodes in musculoskeletal disorders (like sprains and strains), acute low back pain, and managing discomfort following dental extractions or minor surgical procedures. This supports patients during episodes of heightened discomfort and may assist with easing the overall symptom load when symptoms are more noticeable.

Quick Fact: Symptomatic Support
Core Symptom Cluster	Pain, Inflammation, and associated Fever
Relevant Scenarios	Acute episodes, post-procedural discomfort, and recurrent manifestations (e.g., menstrual pain).

Eligibility Map: Who can and cannot use Delfenac — official regulatory information

Official regulatory documents define strict criteria for using the combination medicine Delfenac (Aceclofenac/Paracetamol).

Category	Official Regulatory Status
Populations for whom use is allowed	Adults are the standard population for whom use is generally established.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Aceclofenac, Paracetamol, aspirin, or other NSAIDs.
	Patients with severe heart failure (NYHA Class II-IV), severe hepatic impairment, or severe renal impairment.
	Patients with active or history of recurrent peptic ulcer/haemorrhage or GI perforation.
	Use during the third trimester of pregnancy is contraindicated.
Age-related eligibility rules	Children and adolescents (typically under 18 years) are not recommended for use as safety and efficacy have not been established. Older adults require close medical surveillance and caution due to increased risk of adverse effects.
Pregnancy and lactation status	First/Second Trimesters & Lactation are not recommended unless specifically deemed necessary as per labeling. Third Trimester use is strictly contraindicated.
Eligibility-related restrictions	Caution is required for patients with pre-existing conditions like uncontrolled hypertension, Ischaemic Heart Disease, ulcerative colitis, or Crohn's disease.

These guidelines establish mandatory exclusions for specific patient groups, such as those with severe organ failure or a history of recurrent GI bleeding, ensuring the official label restrictions are adhered to. Restricted use applies to patients with milder organ impairment or certain cardiovascular conditions.

Official Regulatory Interactions with other medicines and products for Delfenac

The interaction profile for Delfenac (Aceclofenac/Paracetamol) is defined by officially documented effects on drug exposure and additive toxicity risks, as stated in regulatory labels.

Category	Official Regulatory Documentation Summary
Medicinal Product Categories	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anticoagulants, Diuretics, Corticosteroids, Immunosuppressants (e.g., Cyclosporine), Drugs that Induce Hepatic Microsomal Enzymes.
Specific Interacting Medicines	Lithium, Methotrexate, Digoxin, Mifepristone, Cholestyramine, Probenecid, Rifampicin, Isoniazid, Antiepileptic drugs, and other Paracetamol-containing products.
Mechanistic Basis of Interactions	Inhibition of renal clearance (e.g., for Lithium, Methotrexate); Enhanced systemic toxicity (e.g., nephrotoxicity); Altered absorption rate; Hepatic microsomal enzyme induction (leading to Paracetamol toxicity).

Interaction-Related Restrictions

• Contraindicated/Avoided Combinations: Co-administration with other NSAIDs (including COX-2 inhibitors) and Corticosteroids is officially advised to be avoided due to the increased risk of gastrointestinal adverse effects. Combining Delfenac with other Paracetamol-containing products is contraindicated.
• Mandatory Timing Rules: Delfenac must not be used for 8–12 days following Mifepristone administration. A separation of at least one hour is required between Delfenac and Cholestyramine.
• Substance Restriction: Consumption of Alcohol is restricted due to the documented risks of gastrointestinal bleeding and enhanced liver toxicity.

Official Interaction Statements

Regulatory documents state that co-administration with Lithium and Methotrexate formally increases their plasma concentrations. The use with Anticoagulants is noted to enhance their activity, and the combination with Cyclosporine enhances the risk of nephrotoxicity. These constraints also extend to Elderly Patients due to the higher potential for altered renal or hepatic function, which modifies the clinical significance of documented interactions.

Targeting the COX Enzyme System

Delfenac's primary biological action involves the inhibition of both the Cyclooxygenase-1 (COX -1) and Cyclooxygenase-2 (COX -2) enzymes. This foundational molecular step restricts the conversion of arachidonic acid into prostaglandins, which function as lipid mediators.

---

Modulating Inflammatory and Nociceptive Cascades

By suppressing prostaglandin synthesis, the mechanism restricts the activity of key inflammatory signaling pathways that are activated by tissue damage. This cascade leads to a decrease in the local chemical sensitization of nociceptors and reduced synthesis of mediators linked to edema and thermoregulatory changes.

---

Balancing Constitutive vs. Inducible Effects

The mechanism is classified as non-selective, affecting both the inducible COX -2 and the constitutive COX -1 enzyme. This action modulates heightened inflammatory signaling but also affects constitutive homeostatic systems necessary for gastric mucosal integrity and renal blood flow regulation.

How Delfenac is Used in Clinical Practice

This section describes the administration guidelines for the Delfenac fixed-dose combination tablet. The administration of Delfenac is structured by rules regarding the route, frequency, and conditions of intake.

Administration Scope	Guideline
Route of Administration	The approved route is oral via the solid, fixed-dose tablet.
Standard Dosing Schedule	The maximum recommended daily dose for adults is two tablets daily. This regimen provides 200 mg of the Aceclofenac component per day.
Timing in Relation to Meals	The tablet is advised to be taken with or immediately after food to minimize potential gastrointestinal effects.
Frequency Pattern	The total daily dose is administered in a divided regimen, typically one tablet taken in the morning and one in the evening.
Duration Principle	Treatment must employ the lowest effective dose for the shortest possible duration necessary to control symptoms.

---

Standard instructions specify that the fixed-dose tablet must be swallowed whole using liquid and should not be crushed, broken, or chewed. Dose adjustments are addressed for specific patient groups; for instance, a reduced initial daily dose (equivalent to 100 mg of the Aceclofenac component) is suggested for patients with hepatic impairment. Use in the pediatric population (under 18 years) is generally not recommended due to a lack of clinical data. Adherence to the prescribed frequency is critical; if a dose is missed, it is recommended to take the next dose at the usual time and strictly avoid a double dose to compensate.

Research Evidence / Overview of Studies for Delfenac

Evidence for Chronic Inflammatory Conditions

Research was studied for use related to conditions characterized by fluctuating manifestations like Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). The research base includes short-term randomized controlled trials (RCTs) and systematic reviews, with studies exploring outcomes related to physical discomfort and daily functioning. Comparative trials evaluated outcomes such as pain intensity difference, often studying the combination against monotherapy. For RA and AS, evidence is limited and largely reflects evidence from studies of the Aceclofenac component alone.

Evidence for Acute Pain and Musculoskeletal Episodes

Delfenac was studied for use in acute scenarios, including Acute Low Back Pain and post-procedural discomfort. Systematic reviews reported low-to-moderate certainty evidence regarding pain reduction measurements in immediate-term follow-up. Certain guideline-informing research indicated that single-agent Paracetamol was associated with limited measured outcomes for acute low back pain. Comparative evidence is lacking for large-scale RCTs specifically focused on this combination across the broad range of acute musculoskeletal injuries.

Durability of Effect and Uncertainties

The majority of key clinical trials were designed for short-term observation, ranging from 10 days to up to six months. Because the focus of key trials has been on short-term outcomes and safety, there is limited information for long-term outcomes that describe the sustained duration of symptom management. Long-term effects are not fully established. Follow-up durations were limited in many combination-specific trials, and the evidence quality varies across studies.

Research in Specific Patient Groups

Evidence applied in studies examining patient-reported experiences primarily involves the general adult population. Research focused exclusively on specific groups, such as older adults, pregnant individuals, or children evidence is limited. Consequently, the results apply only to the populations studied in the primary clinical trials.

Key Studies & References Aceclofenac and Paracetamol Tablets - Summary of Product Characteristics (NAFDAC Regulatory Document)

Common questions about Delfenac (FAQ)

Q: Is Delfenac considered a narcotic or opioid pain reliever?

A: Regulatory documents classify this medicine as a Non-Steroidal Anti-Inflammatory Drug (NSAID) combined with an analgesic (Paracetamol).

It is not classified as an opioid or narcotic pain reliever. It is used to address inflammation and pain related to musculoskeletal conditions.

---

Q: How is Delfenac different from other common over-the-counter pain relievers?

A: The key difference is that Delfenac is a prescription-only combination product.

It includes the anti-inflammatory component Aceclofenac, which requires a prescription, alongside the common over-the-counter analgesic Paracetamol. This composition distinguishes it from single-agent pain relievers typically available without a prescription.

---

Q: Can Delfenac be used for chronic nerve pain or neuropathy?

A: Official regulatory documents indicate this medicine is approved for the relief of pain and inflammation in conditions such as Osteoarthritis, Rheumatoid Arthritis, and acute musculoskeletal disorders.

The official label does not specifically list chronic nerve pain or neuropathy as an approved indication for the medicine.

---

Q: What are the recognized signs of a severe allergic reaction to Delfenac?

A: The official product information notes the potential for hypersensitivity reactions, which are a type of severe allergic response.

Recognized signs documented in regulatory sources include rash and angioedema, which is swelling beneath the skin.

---

Q: How long can a person continuously use Delfenac, according to regulatory documents?

A: Regulatory documents state that use is based on the lowest effective dose for the shortest duration necessary to control symptoms.

Official instructions emphasize a principle of minimizing exposure, rather than setting a specific maximum number of days for all patients.

---

Q: Is it common to feel dizzy or drowsy when first starting Delfenac?

A: Dizziness is documented in regulatory sources as a common undesirable effect, and drowsiness has also been reported in the product information.

Official information does not specifically address the frequency of these effects when first starting the treatment.

---

Q: How quickly should I expect Delfenac to start providing relief?

A: Scientific information shows that the active ingredient Aceclofenac is absorbed rapidly after intake.

Peak concentrations in the body are typically reached in approximately 1.25 to 3 hours after administration.

---

Q: How long does the primary effect of a single dose of Delfenac typically last?

A: Regulatory data indicates that the active ingredient has a half-life of approximately 4 to 5 hours.

Relief generally lasts 8–12 hours, and the half-life supports a frequency of administration generally taken in a divided daily regimen.

---

Q: What is the statistical risk of gastrointestinal bleeding associated with Delfenac use?

A: Official labeling contains specific and serious warnings regarding the potential for adverse reactions affecting the digestive tract.

These warnings include the risk of gastrointestinal bleeding, ulceration, or perforation.

---

Q: Can Delfenac be taken at the same time as low-dose aspirin?

A: Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including aspirin, is advised to be avoided in the official documents.

This restriction is due to an increased risk of gastrointestinal adverse effects when the drugs are combined.

---

Q: Does Delfenac interact with common dietary supplements like Vitamin D or magnesium?

A: The official interaction documentation notes that certain supplements, such as Ginkgo biloba, garlic, or ginger, may increase the risk of bleeding.

Other common vitamin and mineral supplements are not typically addressed in the general regulatory documents.

---

Q: Are there any specific foods or drinks that interact with Delfenac?

A: The medicine's official instructions require that it be taken with or immediately after food to help minimize potential stomach effects.

The consumption of Alcohol is restricted in the product documentation due to documented risks of gastrointestinal bleeding and potential liver toxicity.

---

Q: What kinds of over-the-counter medicines should be avoided while using Delfenac?

A: Official guidance states that the use of other Paracetamol-containing products is contraindicated.

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is also advised to be avoided.

---

Q: Is Delfenac described in official sources as having a risk of dependence or addiction?

A: Regulatory documents classify this medicine as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and an analgesic, not an opioid.

Therefore, the official product label does not contain warnings regarding the risk of dependence or addiction, which are legally required for opioid pain medicines.

---

Q: Does Delfenac affect the effectiveness or metabolism of common hormonal birth control pills?

A: Regulatory documents note that the Paracetamol component may slightly decrease or delay its effects when combined with oral contraceptives.

However, this interaction is generally considered to be of no significant additional risk at the usual therapeutic dosage.

---

Q: What level of scientific evidence supports the use of Delfenac for common forms of arthritis?

A: Clinical trials conducted for the product's authorization show that it is an effective NSAID for the treatment of rheumatoid arthritis and osteoarthritis.

This evidence is based on data gathered from short-term controlled studies.

---

Q: What does it mean for a drug like Delfenac to have a 'black box warning'?

A: Regulatory documents contain serious warnings about the potential for adverse effects within the drug class.

These warnings specifically concern the potential for serious Cardiovascular thrombotic events (such as heart attack and stroke) and the risk of serious, sometimes fatal, gastrointestinal adverse events.

---

Q: Is a mild, temporary headache considered a normal initial reaction to Delfenac?

A: Headache is listed in regulatory documents as a common undesirable effect.

Official safety information classifies adverse events by frequency but does not categorize reactions as 'temporary' or 'normal initial reaction'.

---

Q: Does Delfenac interact with common medications prescribed for high blood pressure?

A: This medicine may interact with certain medications prescribed for high blood pressure.

Official documents indicate it may reduce the effectiveness of some treatments, such as Diuretics and antihypertensives, and could potentially affect kidney function when used in combination.

---

Q: What official information is available regarding weight changes or fluid retention while using Delfenac?

A: Official documentation confirms that Oedema (swelling due to fluid retention) has been reported as an undesirable effect.

This is a potential reaction that is monitored by health agencies.

---

Q: Are there any general restrictions on driving or operating machinery while taking Delfenac?

A: Due to the potential for effects like dizziness and visual disturbance, the official prescribing information advises avoiding driving or operating machinery.

This instruction is included to minimize risks while taking the medicine.

---

Q: What is the main purpose of Delfenac's inactive ingredients?

A: The inactive ingredients, also known as excipients, are listed in regulatory documents.

Their main purpose is to function as formulation components such as binders, lubricants, and coating agents to ensure the tablet can be correctly manufactured and absorbed.

---

Q: What is the scientific basis for the recommended storage conditions for Delfenac?

A: The specific storage conditions, such as storing below 30 C and protecting from light and moisture, are mandated by regulators.

These rules are put in place to maintain the certified stability and effectiveness of the product over its shelf life.

How to Store and Dispose of Delfenac

Storage and disposal of Delfenac (Aceclofenac/Paracetamol tablets) must follow official regulatory requirements to maintain product stability and ensure safety.

Official Storage Conditions

Requirement	Specifics
Temperature Limit	Store below 30 C (86 F).
Environmental Protection	Protect from both light and moisture; keep dry.
Packaging Rule	Must be stored in the original package.
Shelf Life	Stability is certified for 36 months when stored under the labeled conditions.
Child Safety	Keep out of the sight and reach of children and pets.

Disposal Instructions

Any unused or expired product should be disposed of in accordance with local requirements. The medicine should not be discarded into the wastewater system or ordinary household trash.